U.S. Markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.06 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,816.90
    -18.90 (-1.03%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1872
    -0.0024 (-0.2018%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • Vix

    18.24
    +0.54 (+3.05%)
     
  • GBP/USD

    1.3908
    -0.0050 (-0.3547%)
     
  • USD/JPY

    109.6500
    +0.1890 (+0.1727%)
     
  • BTC-USD

    41,723.35
    -238.56 (-0.57%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

MYND Life Sciences to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

·1 min read

VANCOUVER, BC, June 15, 2021 /CNW/ - MYND Life Sciences Inc. (CSE: MYND) ("MYND") a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce that CEO, Dr. Lyle Oberg, will be presenting at the "Psychedelics in Psychiatry and Beyond" conference sponsored by H.C. Wainwright & Co.

MYND Life Sciences Inc. Logo (CNW Group/Mynd Life Sciences Inc.)
MYND Life Sciences Inc. Logo (CNW Group/Mynd Life Sciences Inc.)

The conference will be held virtually on Thursday, June 17, 2021. Dr. Oberg will provide an overview of MYND's business, intellectual property holdings and its pipeline towards both a novel diagnostic and drug innovation for treating and diagnosing depression and other diseases of neuroinflammation.

Details of the presentation are as follows:

Date:

Thursday, June 17th, 2021

Time:

MYND's presentation will be available to access beginning at 9:30EDT

Registration:

https://hcwevents.com/psychedelics/

For more information and to subscribe to the Company's mailing list, please visit https://myndsciences.com/contact/

ABOUT MYND LIFE SCIENCES

MYND Life Sciences is a psychedelic medicine biotech company focused on neuro-pharmaceutical drug development. The Company is advancing psychedelic derived medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials with an initial focus on Major Depressive Disorder.

CONTACT INFORMATION
Dr. Lyle Oberg, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/mynd-life-sciences-to-present-at-hc-wainwright-psychedelics-in-psychiatry-and-beyond-virtual-conference-301312365.html

SOURCE Mynd Life Sciences Inc.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2021/15/c6430.html